Published in Oxid Med Cell Longev on May 15, 2012
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia | NCT00596011
Resources and biological activities of natural polyphenols. Nutrients (2014) 1.17
Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog (2013) 1.11
Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism. PLoS One (2012) 0.97
Dietary antiaging phytochemicals and mechanisms associated with prolonged survival. J Nutr Biochem (2014) 0.88
ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid Med Cell Longev (2016) 0.85
Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitis. J Tradit Complement Med (2014) 0.84
Roles of autophagy induced by natural compounds in prostate cancer. Biomed Res Int (2015) 0.80
Dietary Antioxidant and Flavonoid Intakes Are Reduced in the Elderly. Oxid Med Cell Longev (2015) 0.78
An overview on the role of dietary phenolics for the treatment of cancers. Nutr J (2016) 0.76
Breast cancer chemopreventive and chemotherapeutic effects of Camellia Sinensis (green tea): an updated review. Electron Physician (2017) 0.75
Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. Antioxidants (Basel) (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Chromatin modifications and their function. Cell (2007) 55.98
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev (2003) 17.64
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 9.27
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Cellular memory and the histone code. Cell (2002) 7.30
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
Widespread deregulation of microRNA expression in human prostate cancer. Oncogene (2007) 5.70
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst (1968) 4.68
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Loss of mir-146a function in hormone-refractory prostate cancer. RNA (2008) 3.35
The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell (1993) 3.27
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer (1991) 3.14
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res (2003) 2.80
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A (2001) 2.79
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene (2009) 2.61
Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev (1999) 2.51
The chemistry of tea flavonoids. Crit Rev Food Sci Nutr (1997) 2.51
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst (1997) 2.39
Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol (2007) 2.38
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res (1989) 2.18
Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer (2010) 2.13
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res (2005) 2.07
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev (2001) 1.87
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res (2004) 1.84
Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer (2004) 1.80
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol (2005) 1.78
MicroRNAs make big impression in disease after disease. Science (2008) 1.67
Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene (2003) 1.62
MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene (2009) 1.61
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res (2007) 1.58
Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene (2007) 1.57
Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) (2009) 1.56
Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol (2000) 1.55
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett (1995) 1.48
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther (2008) 1.48
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology (2009) 1.47
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer (2011) 1.46
Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J (2005) 1.45
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
Molecular targets for green tea in prostate cancer prevention. J Nutr (2003) 1.43
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys (2003) 1.39
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine (2010) 1.37
Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol (2007) 1.35
Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res (2000) 1.31
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics (2011) 1.31
Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem (2011) 1.30
Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate (2007) 1.29
A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control (2004) 1.28
Cancer prevention by tea: Evidence from laboratory studies. Pharmacol Res (2011) 1.28
Green tea and cancer prevention. Nutr Cancer (2010) 1.25
Prostate Cancer Working Group report. Jpn J Clin Oncol (2010) 1.25
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology (2007) 1.24
A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol (2005) 1.23
Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer (2010) 1.22
Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer (2009) 1.22
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res (2009) 1.21
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis (2005) 1.19
Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr (2006) 1.18
The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis (2004) 1.18
Debate continues on use of PSA testing for early detection of prostate cancer. JAMA (2011) 1.16
Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta (2008) 1.16
Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol (2001) 1.16
Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer (2011) 1.16
Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci (2001) 1.16
Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev (2007) 1.14
Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res (2008) 1.14
Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res (2005) 1.13
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Recognition and cleavage of primary microRNA transcripts. Methods Mol Biol (2006) 1.11
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2010) 1.11
Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol (2012) 1.10
Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer (2005) 1.09
Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr (2003) 1.08
No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer (2006) 1.08
Antioxidant chemistry of green tea catechins. New oxidation products of (-)-epigallocatechin gallate and (-)-epigallocatechin from their reactions with peroxyl radicals. Chem Res Toxicol (2000) 1.08
Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res (2010) 1.08
Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol Sin (2007) 1.06
O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metab Dispos (2000) 1.06
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol (2009) 2.71
Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res (2010) 1.94
Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension (2011) 1.89
Management of stage T1 tumors of the bladder: International Consensus Panel. Urology (2005) 1.81
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol (2011) 1.62
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol (2009) 1.34
Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res (2011) 1.30
MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res (2012) 1.19
Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail (2010) 1.19
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology (2008) 1.19
Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res (2011) 1.18
The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis (2004) 1.18
Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler Thromb Vasc Biol (2007) 1.16
Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev (2008) 1.15
Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res (2004) 1.14
The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer (2010) 1.12
Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol (2010) 1.08
Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci (2007) 1.07
Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer (2004) 1.05
Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes (2012) 1.00
Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol (2007) 0.97
Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol (2004) 0.96
Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res (2004) 0.96
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Prostate cancer stem cells: are they androgen-responsive? Mol Cell Endocrinol (2011) 0.94
Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther (2013) 0.94
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia (2007) 0.93
Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res (2009) 0.93
Clusterin (CLU) and lung cancer. Adv Cancer Res (2009) 0.92
Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression (review). Oncol Rep (2007) 0.91
Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol (2010) 0.88
Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res (2007) 0.88
Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis (2005) 0.88
Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. Carcinogenesis (2013) 0.87
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol (2009) 0.87
Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells. J Cell Physiol (2006) 0.87
Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology (2002) 0.86
Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch (2002) 0.86
Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol (2013) 0.86
Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells. Toxicol Sci (2011) 0.85
Clusterin (CLU) and prostate cancer. Adv Cancer Res (2009) 0.85
Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic Acids Res (2012) 0.85
Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem J (2004) 0.84
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int (2007) 0.83
Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. Am J Respir Crit Care Med (2006) 0.83
Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Exp Cell Res (2010) 0.83
Chapter 5: Nuclear CLU (nCLU) and the fate of the cell. Adv Cancer Res (2009) 0.82
Stromal upregulation of lateral epithelial adhesions: gene expression analysis of signalling pathways in prostate epithelium. J Biomed Sci (2011) 0.82
Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol (2011) 0.82
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS One (2013) 0.82
B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival. Blood Cells Mol Dis (2007) 0.82
Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. Int J Oncol (2011) 0.82
Preparation of magnetic carbon nanotubes (Mag-CNTs) for biomedical and biotechnological applications. Int J Mol Sci (2013) 0.81
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One (2011) 0.81
Chapter 2: Clusterin (CLU): From one gene and two transcripts to many proteins. Adv Cancer Res (2009) 0.81
Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis (2005) 0.80
Establishment of an organotypic in vitro culture system and its relevance to the characterization of human prostate epithelial cancer cells and their stromal interactions. Pathol Res Pract (2007) 0.80
Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res (2003) 0.80
Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing. Int J Oncol (2011) 0.80
The future of urology. Eur Urol (2011) 0.79
Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int (2011) 0.79
Chapter 3: The shifting balance between CLU forms during tumor progression. Adv Cancer Res (2009) 0.79
Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet (2012) 0.79
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol (2012) 0.78
Prognostic role of clusterin in resected adenocarcinomas of the lung. Lung Cancer (2012) 0.78